A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

Phase 1 Terminated 18 enrolled GlaxoSmithKline

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, open label, two-part study to determine recommended phase 2 dose (RP2D) and schedule of GSK3745417 administration in participants with relapsed/refractory AML or HR-MDS.

Timeline

Start: 2022-09-20
Primary completion: 2024-03-04
Completion: 2024-03-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GSK3745417	Unknown	—	Intravenous

A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

Summary

Timeline

Drugs

Indications